BROWSE ALL ARTICLES BY TOPIC
Articles by Keyword - SLE
Listing articles 1 to 10 of 11
Differences in disease manifestations, severity, and management require special consideration from rheumatologists who treat children and adolescents with systemic lupus erythematosus
Features: ACR 2013 State-of-the-Art Clinical Symposium: What's Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
Experts highlight treatment advances and challenges ahead in OA, RA, and systemic lupus erythematosus (SLE)
Meeting: California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients
A systemic lupus erythematosus (SLE) disease expert emphasizes benefits of hydroxychloroquine, burst of steroid treatments
Researchers treated mouse model of systemic lupus erythematous with mycophenolic acid delivered via nanoparticle. (posted June 18, 2013)
Meeting: ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
Studying factors that may lead to life-threatening comorbidities such as lymphoma and thrombosis could give rheumatologists clearer direction on treating patients with SLE
Advances in SLE, osteoporosis, and RA highlighted at California Rheumatology Alliance meeting.
More than 90% of systemic lupus erythematosus (SLE) patients experience a communication gap with their family and with their care team, according to a recent survey conducted by GfK Roper North America. The survey found that many SLE patients downplay their symptoms to friends, family, and even their doctors.
More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. "Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.
It is well known that systemic lupus erythematosus (SLE) disproportionately affects women and members of racial and ethnic minorities, and that persons with SLE of lower socioeconomic status have poorer outcomes of disease and higher death rates. The combination of SLE’s increased prevalence among minorities and women and its complexity, which leads to a need to have access to a wide range of healthcare services, makes SLE an important case study of how people of a racial or ethnic minority or...
News: Safety First
Phase 1 clinical trials begin the process of moving a potential medication from the laboratory to the patient. Unlike the later types of studies, the focus of Phase 1 investigations is to clarify the appropriate dose of the agent, define a preliminary toxicity profile, and describe its pharmacokinetics.